How Long Do Retatrutide Side Effects Last? What the Trials Show

Side effects on retatrutide mostly follow your dose steps. How long do retatrutide side effects last? In Lilly's trials, stomach side effects bunched up in the weeks when the dose was rising, then subsided over time, while heart rate ran on a slower clock of its own. No trial has published a day count for each symptom, and this guide flags that gap wherever it matters.

Nobody starts a weekly shot hoping to feel sick for a month. And when nausea or a pounding pulse shows up, the real question is whether it is a phase or your new normal. The trial data answer that better than most pages admit, so here is what they show, window by window.

When do retatrutide side effects start?

Most stomach side effects show up while the dose climbs. Lilly reported that in its Phase 2 obesity trial they usually came during the dose escalation period. In the Phase 3 TRANSCEND-T2D-1 trial, nausea, diarrhea and vomiting also occurred mainly during escalation.

Escalation begins with your very first shot. In every Phase 3 trial Lilly has reported, people started at 2 mg once a week and stepped up every 4 weeks (2, 4, 6, 9, then 12 mg), so reaching 12 mg took 16 weeks. In the Phase 2 obesity trial, all dose steps were finished by week 12.

No trial has published the exact day symptoms begin. One clue comes from the tirzepatide label, which says that drug's slowing of stomach emptying is largest after the first dose and fades over time. That is class evidence from a related drug, not retatrutide data, but it matches the pattern of symptoms bunching early.

User forums echo this. One r/Retatrutide post, for example, asks for help after bad side effects in the first week on the drug. Treat posts like that as reports, not evidence, and use our retatrutide dosing schedule to see where each step falls.

How long do retatrutide side effects last, window by window

Think in windows rather than one countdown. Here is what the published data support for each stage, and where the data stop.

The trials tell you when side effects bunch up, not how many days yours will last. That makes your own pattern across one or two dose steps the most useful data you will get.

How long each common side effect usually lasts

Each symptom follows its own pattern, with its own gaps. The table pairs how common each one was with what the data say about timing.

Nausea, diarrhea and vomiting

These are the classic dose-step symptoms. The 2026 Lancet report of TRANSCEND-T2D-1 described them as mostly mild to moderate and said they subsided over time, and a Nature Medicine analysis of Phase 2 participants with fatty liver called them transient. For ways to take the edge off while they settle, see our guide to retatrutide nausea.

Constipation is less clear. Lilly listed it among the most common side effects but did not describe its timing, so the data cannot tell you whether it fades on the same schedule.

Heart rate

Heart rate follows a slower clock. In the Phase 2 obesity trial, the rise in heart rate grew with dose, peaked at week 24 and then declined, even though the last dose step came at week 12. The published abstract does not give the size of the rise; for comparison only, the tirzepatide label reports an average increase of 1 to 3 beats per minute. If your heart races or pounds while you are at rest, tell your clinician, as the Wegovy label asks patients to do.

Skin sensitivity

Dysesthesia means altered skin sensation: skin that feels sore, burning or oversensitive to touch. Across the five Phase 3 trials it affected 2.3% to 20.9% of people on retatrutide, versus 0% to 1.3% on placebo, with the highest rate on 12 mg in TRIUMPH-4. Lilly reported that most cases were mild to moderate and that the majority resolved while people stayed on treatment, but how long a typical episode lasts has not been published.

Fatigue, sleep and injection sites

Fatigue showed up in 10% of the 12 mg group in the Phase 2 obesity trial versus 4% on placebo, with no timing data. Sleep problems and injection site reactions did not reach the 5% reporting threshold in any group of either Phase 2 trial. Sleep complaints still come up often in user forums, and our retatrutide insomnia guide covers that side of things.

Why side effects come back after a dose increase

A new dose step can restart the adjustment. The trials concentrated stomach side effects in the escalation weeks, and Phase 2 showed that the size of the jump matters. People who started at 4 mg instead of 2 mg had far more nausea on the same target dose.

Nausea on placebo was 11% in the obesity trial and 4% in the diabetes trial. In the diabetes trial, stomach side effects overall were mild to moderate and most frequent, at 50%, in the 8 mg group that started at 4 mg. The Phase 2 results informed Phase 3 dose selection, and every reported Phase 3 trial then started at 2 mg with 4-week steps.

A likely part of the reason is adaptation. The tirzepatide label's note that stomach slowing is largest after the first dose suggests the gut settles into a given dose, and a bigger dose asks it to adjust again. That is a reasonable reading of class evidence, not something measured for retatrutide.

Skin sensitivity can come back too, at least with a related drug. On semaglutide 7.2 mg, 17 of 38 people (45%) who were stepped back up after their dysesthesia resolved had it come back, according to the Wegovy label. Treat that as a warning sign for retatrutide rather than a forecast.

User reports describe the same build-up. One r/Retatrutide post describes climbing from 2.5 mg to 10 mg a week over 8 months, then scaling back to 2.5 mg because the side effects of the large dose wore them down.

Do retatrutide side effects go away?

In the trials, mostly yes, and most people stayed on. The 2026 Lancet paper on TRANSCEND-T2D-1 reported that the stomach side effects subsided over time, and only 2% to 5% of people on retatrutide stopped because of side effects, against 0% on placebo.

In the obesity trials, stopping for side effects was generally higher at higher doses. In TRIUMPH-1 it was 4.1%, 6.9% and 11.3% on 4, 9 and 12 mg, against 4.9% on placebo. In TRIUMPH-4 it reached 18.2% on 12 mg, a rate Lilly said tracked with starting BMI and included people who felt they were losing too much weight.

What the trials do not show is how many people had a symptom that never fully cleared. Stopping rates only count people who quit, not people who pushed through symptoms that lingered.

What if your side effects do not fade?

Stalled improvement is a signal, not a test of willpower. Even inside Lilly's trials, stepping down was allowed: the TRIUMPH-1 extension only enrolled people who finished without a permanent dose reduction, which tells you such reductions were part of the protocol.

Approved drugs in the same class build that flexibility into their labels. The Wegovy label says to consider delaying the next step by 4 weeks if a dose is not tolerated, and the Zepbound label suggests a lower maintenance dose for people who do not tolerate theirs. On semaglutide 7.2 mg, skin sensitivity resolved faster when the dose was lowered, paused or stopped than when nothing changed.

So if a symptom is not easing at a steady dose, talk with your clinician about holding your current dose longer or stepping back to the last one you tolerated. Changing the dose is a decision to make with them, not on a forum's say-so.

Check the product as well. No approved version exists yet, and Lilly plans to submit retatrutide to the FDA in the first quarter of 2027. Lilly also warns that products sold outside its trials may contain too much or too little active ingredient. A vial stronger than its label acts like a dose step you never planned, so if you are comparing retatrutide for sale, favor sellers that publish batch-specific third-party tests for identity and content.

How long do side effects last after stopping?

Stopping does not switch retatrutide off overnight. With a half-life of about 6 days, blood levels fall by roughly half each week after your last shot, so the drug takes several weeks to clear. No retatrutide trial has published how quickly side effects fade after stopping.

Because levels fall gradually, it is reasonable to expect effects to taper rather than stop on day one. Tell your clinician about anything that lingers or starts after you stop, and see our guide to retatrutide long-term side effects for the bigger picture on staying on or coming off.